20/20 Biolabs Inc (AIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 03-2025 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 4,219 | 1,026 | N/A |
| Receivables | 202 | 200 | N/A |
| Inventories | 105 | 116 | N/A |
| TOTAL | $4,700 | $1,471 | $N/A |
| Non-Current Assets | |||
| PPE Net | 45 | 57 | N/A |
| Intangibles | 1,035 | 1,079 | 0 |
| Other Non-Current Assets | 23 | 1,531 | 0 |
| TOTAL | $1,103 | $2,666 | $N/A |
| Total Assets | $5,803 | $4,137 | $N/A |
| Liabilities | |||
| Current Liabilities | |||
| Short Term Debt | 307 | 75 | N/A |
| Accounts payable and accrued liabilities | 981 | 869 | 0 |
| Accrued Expenses | 598 | 786 | N/A |
| Other current liabilities | N/A | 143 | N/A |
| TOTAL | $2,580 | $2,463 | $N/A |
| Non-Current Liabilities | |||
| Deferred Revenues | 451 | 415 | N/A |
| Other Non-Current Liabilities | 429 | 1,652 | 0 |
| TOTAL | $466 | $1,693 | $N/A |
| Total Liabilities | $3,046 | $4,157 | $N/A |
| Shareholders' Equity | |||
| Shares Outstanding, K | 10,612 | N/A | N/A |
| Common Shares | 104 | 54 | N/A |
| Retained earnings | -35,422 | -33,247 | N/A |
| TOTAL | $2,757 | $-19 | $N/A |
| Total Liabilities And Equity | $5,803 | $4,137 | $0 |